Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren Antiproteinuric Effect in T2D Nephropathy
NCT00461136Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aliskiren in diabetic nephropathy (DN), sponsored by Novartis. Primary endpoint: Time-course of the antiproteinuric effect. Started Aug 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00461136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461136.